Media coverage about Blueprint Medicines Corporation (NASDAQ:BPMC) has trended somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Blueprint Medicines Corporation earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.6259287998293 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern’s scoring:
- Chief Business Officer of Blueprint Medicines Corporation (NASDAQ:BPMC), Haviland Kate, sells 5,449 shares worth $362,033 (empowerednews.net)
- Kate Haviland Sells 5,449 Shares of Blueprint Medicines Corporation (BPMC) Stock (americanbankingnews.com)
- Blueprint Medicines Announces Appointment of Christopher Murray, – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Blueprint Medicines Corporation (BPMC) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
A number of analysts have recently issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $56.00 target price on shares of Blueprint Medicines Corporation in a research report on Tuesday, September 5th. BidaskClub raised Blueprint Medicines Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Wedbush reaffirmed an “outperform” rating and set a $66.00 target price on shares of Blueprint Medicines Corporation in a research report on Tuesday, August 22nd. Zacks Investment Research lowered Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Finally, BTIG Research assumed coverage on Blueprint Medicines Corporation in a research report on Friday, September 29th. They set a “buy” rating and a $90.00 target price on the stock. One analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. Blueprint Medicines Corporation currently has a consensus rating of “Buy” and an average price target of $63.47.
Shares of Blueprint Medicines Corporation (NASDAQ BPMC) opened at 67.66 on Wednesday. Blueprint Medicines Corporation has a one year low of $25.08 and a one year high of $71.67. The company’s market capitalization is $2.65 billion. The company has a 50-day moving average price of $58.96 and a 200 day moving average price of $48.72.
Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.11). The company had revenue of $5.89 million for the quarter, compared to analyst estimates of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The firm’s quarterly revenue was down 16.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.70) EPS. On average, analysts forecast that Blueprint Medicines Corporation will post ($3.66) EPS for the current fiscal year.
In related news, insider Kate Haviland sold 5,449 shares of the stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $66.44, for a total value of $362,031.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $49.08, for a total transaction of $981,600.00. Following the completion of the transaction, the chief executive officer now directly owns 18,272 shares of the company’s stock, valued at approximately $896,789.76. The disclosure for this sale can be found here. Insiders have sold 69,305 shares of company stock valued at $3,606,782 in the last ninety days. 3.40% of the stock is owned by company insiders.
Blueprint Medicines Corporation Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.